CAR.AU

39.48

+0.61%↑

WOR.AU

14.64

+0.55%↑

AZJ.AU

3.19

+0.31%↑

RSG.AU

0.69

0%↓

CAR.AU

39.48

+0.61%↑

WOR.AU

14.64

+0.55%↑

AZJ.AU

3.19

+0.31%↑

RSG.AU

0.69

0%↓

CAR.AU

39.48

+0.61%↑

WOR.AU

14.64

+0.55%↑

AZJ.AU

3.19

+0.31%↑

RSG.AU

0.69

0%↓

CAR.AU

39.48

+0.61%↑

WOR.AU

14.64

+0.55%↑

AZJ.AU

3.19

+0.31%↑

RSG.AU

0.69

0%↓

CAR.AU

39.48

+0.61%↑

WOR.AU

14.64

+0.55%↑

AZJ.AU

3.19

+0.31%↑

RSG.AU

0.69

0%↓

Search

CSL Ltd

Closed

SectorIndustrials

210.17 0.15

Overview

Share price change

24h

Current

Min

209.19

Max

210.4

Key metrics

By Trading Economics

Income

2B

Sales

-5.7B

2.5B

P/E

Sector Avg

21.941

38.367

EPS

2.04

Dividend yield

1.39

Profit margin

24.437

Employees

29,904

EBITDA

-2.4B

858M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+35.44% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

1.39%

2.26%

Market Stats

By TradingEconomics

Market Cap

-24B

100B

Previous open

210.02

Previous close

210.17

News Sentiment

By Acuity

38%

62%

142 / 459 Ranking in Industrials

CSL Ltd Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

19 sie 2025, 03:32 UTC

Major Market Movers

CSL Shares Slide 13% After Earnings, Seqirus Spin-Off Announcement

18 sie 2025, 23:46 UTC

Earnings

CSL to Spin Off Seqirus, Cut Up to 15% of Staff in Sweeping Restructure -- Update

18 sie 2025, 22:15 UTC

Earnings

CSL to Cut Up to 15% of Staff in $770 Million Restructure

9 kwi 2025, 09:39 UTC

Major Market Movers

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

10 lut 2025, 21:55 UTC

Earnings

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business -- Update

10 lut 2025, 21:34 UTC

Earnings

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business

18 sie 2025, 23:46 UTC

Market Talk
Earnings

Investors May Have Lukewarm Reception to CSL's Earnings, Restructure -- Market Talk

18 sie 2025, 21:52 UTC

Earnings

CSL to Record Up to $700M-$770M in FY26 Restructuring Costs>CSL.AU

18 sie 2025, 21:51 UTC

Earnings

CSL to Cut Up to 15% of Staff>CSL.AU

18 sie 2025, 21:49 UTC

Earnings

CSL Says It Closed 22 Underperforming U.S. Plasma Centers in August>CSL.AU

18 sie 2025, 21:49 UTC

Earnings

CSL: Combination Will Deliver Synergies, Revenue Growth Opportunities>CSL.AU

18 sie 2025, 21:48 UTC

Earnings

CSL to Combine Behring and Vifor Medical and Commercial Functions>CSL.AU

18 sie 2025, 21:47 UTC

Earnings

CSL to Integrate R&D, Business Development, Commercial Teams>CSL.AU

18 sie 2025, 21:46 UTC

Earnings

CSL: Transformational Initiatives to Reduce Costs, Simplfy Decision Making>CSL.AU

18 sie 2025, 21:45 UTC

Earnings

CSL to Launch Multiyear Share Buyback in Fiscal 2026>CSL.AU

18 sie 2025, 21:45 UTC

Earnings

CSL Intends Seqirus to Be Listed on the ASX>CSL.AU

18 sie 2025, 21:44 UTC

Earnings

CSL Intends to Demerge Seqirus by End of FY 2026>CSL.AU

18 sie 2025, 21:43 UTC

Earnings

CSL Raises Dividend to $1.62 Vs. $1.45 >CSL.AU

18 sie 2025, 21:43 UTC

Earnings

CSL FY Underlying Net Profit $3.22B Vs. $2.91B>CSL.AU

18 sie 2025, 21:42 UTC

Earnings

CSL FY Rev $15.56B Vs. $14.80B >CSL.AU

18 sie 2025, 21:42 UTC

Earnings

CSL FY Net $3.00B Vs. Net $2.64B >CSL.AU

17 cze 2025, 02:15 UTC

Market Talk

Higher Margins Offered by CSL's Andembry Will Lift Earnings -- Market Talk

9 kwi 2025, 07:01 UTC

Market Talk

CSL May Need to Raise Prices to Offset Trump's Potential Pharma Tariffs -- Market Talk

21 mar 2025, 02:03 UTC

Market Talk

Severe U.S. Influenza Season Could Benefit CSL -- Market Talk

11 lut 2025, 22:30 UTC

Market Talk

Flu Vaccines Proving Problematic for CSL -- Market Talk

10 lut 2025, 21:40 UTC

Earnings

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business -- Update

10 lut 2025, 21:19 UTC

Earnings

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business

10 lut 2025, 21:13 UTC

Earnings

CSL Reaffirms Guidance for FY 2025 Net Profit of US$3.2 Billion-US$3.3 Billion at Constant FX

10 lut 2025, 21:12 UTC

Earnings

CSL Interim Dividend US$1.30/Security

10 lut 2025, 21:12 UTC

Earnings

CSL 1H Revenue US$8.48 Billion, Up 5% on Year

Peer Comparison

Price change

CSL Ltd Forecast

Price Target

By TipRanks

35.44% upside

12 Months Forecast

Average 283.415 AUD  35.44%

High 330 AUD

Low 227.5 AUD

Based on 13 Wall Street analysts offering 12 month price targets forCSL Ltd - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

13 ratings

9

Buy

4

Hold

0

Sell

Sentiment

By Acuity

142 / 459 Ranking in Industrials

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About CSL Ltd

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
help-icon Live chat